Abstract
The major issue in surfactant substitution has been the availability of an efficient and safe preparate. At present the quantitative and especially the qualitative requirements of surfactant are unclear. The evaluation is complex because the severity of RDS varies widely. There are a number of possible preparates that function well both in vitro and in vivo in animals. The first and the best known was that used by Fujiwara et al. (1980). However, the suitability is ultimately evaluated on the basis of controlled trials comparing the outcome and the long-term follow-up.
Supported by grants from the Finnish Academy, the Sigrid Juselius Foundation, the Foundation for Pediatric Research in Finland, and National Institutes of Health (HI-35036).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Enhörning G, Grossman G, Robertson B (1973) Tracheal deposition of surfactant before the first breath. Am Rev Respir Dis 107: 921–926
Friedman WF, George BC (1984) Treatment of congestive heart failure by altering loading conditions of the heart. J Pediatr 106: 697–706
Fujiwara T, Chida S, Watabe Y, Maeta H, Morita T, Abe T (1980) Artificial surfactant therapy in hyaline membrane disease. Lancet 1: 55–59
Hallman M (1984) Antenatal diagnosis of lung maturity. In: Robertson B, Van Golde LMG, Batenburg JJ (eds) Pulmonary surfactant. Elsevier, Amsterdam, pp 419–448
Hallman M, Gluck L (1982) Respiratory distress syndrome — update 1982. Pediatr Clin North Am 29: 1057–1075
Hallman M, Merritt TA, Schneider H, Epstein BL, Mannino F, Edwards DK, Gluck L (1983) Isolation of human surfactant from amniotic fluid and a pilot study of its efficacy in respiratory distress syndrome. Pediatrics 71: 473–482
Hallman M, Merritt TA, Järvenpää A-L, Boynton B, Mannino F, Gluck L, Moore T, Edwards D (1985): Exogenous human surfactant for treatment of severe respiratory distress syndrome: a randomized prospective clinical trial. J Pediatr 106: 963–969
Merritt TA, Hallman M, Bloom B et al. (1986) Prophylactic treatment of very premature infants with human surfactant. N Engl J Med 315: 785–790
Pinkerton KE, Barry BE, O’Neil JJ, Raub JA, Pratt PC, Crapo JD (1982) Morphologic changes in the lung during the lifespan of Fischer 344 Rats. Am J Anat 164: 155–174
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1988 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Hallman, M., Pohjavuori, M., Bry, K., Merritt, T.A. (1988). Human Surfactant from Amniotic Fluid in the Treatment of Respiratory Distress Syndrome. In: Lachmann, B. (eds) Surfactant Replacement Therapy. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-73305-5_17
Download citation
DOI: https://doi.org/10.1007/978-3-642-73305-5_17
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-73307-9
Online ISBN: 978-3-642-73305-5
eBook Packages: Springer Book Archive